CLINICAL_TRIALS
trial_result
· 2012-11-02
Clinical Trial Update: A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis [Phase 3]
Summary
Phase 3 study assessing safety and efficacy of ustekinumab (CNTO 1275) in moderate to severe psoriasis; results were posted in 2012.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Centocor Research & Development, Inc. | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2012-11-02